Three recent collaborations are seeking to develop type 1 diabetes therapies that induce insulin-producing cells to regenerate. The compounds could eventually bypass the need for cell therapy, but they still require complementary therapeutic approaches that halt the autoimmune siege on insulin-producing cells in diabetic patients.